126
Participants
Start Date
October 13, 2008
Primary Completion Date
September 17, 2015
Study Completion Date
September 17, 2015
Liposomal doxorubicin hydrochloride
Liposomal doxorubicin hydrochloride will be administered per dose and schedule specified in the arm description.
Cyclophosphamide
Cyclophosphamide will be administered per dose and schedule specified in the arm description.
Trastuzumab
Trastuzumab will be administered per dose and schedule specified in the arm description.
Free doxorubicin hydrochloride
Free doxorubicin hydrochloride will be administered per dose and schedule specified in the arm description.
Docetaxel
Docetaxel will be administered per dose and schedule specified in the arm description.
Teva Investigational Site 16, Kufstein
Teva Investigational Site 15, Vienna
Teva Investigational Site 9, Brussels
Teva Investigational Site 29, Yvoir
Teva Investigational Site 4, Clichy
Teva Investigational Site 5, Nancy
Teva Investigational Site 33, Reims
Teva Investigational Site 8, Vandœuvre-lès-Nancy
Teva Investigational Site 30, Aachen
Teva Investigational Site 11, Düsseldorf
Teva Investigational Site 25, Düsseldorf
Teva Investigational Site 32, Essen
Teva Investigational Site 34, Loerrach
Teva Investigational Site 14, München
Teva Investigational Site 27, München
Teva Investigational Site 20, Napoli
Teva Investigational Site 23, Roma
Teva Investigational Site 21, Verona
Teva Investigational Site 26, Barcelona
Teva Investigational Site 3, Barcelona
Teva Investigational Site 1, Lleida
Teva Investigational Site 2, Zaragoza
Lead Sponsor
Cephalon, Inc.
INDUSTRY